 |
|
|
| |
An analysis of response rates by fibrosis stage in patients treated with faldaprevir, BI 207127 and ribavirin in the SOUND-C2 study
|
| |
| |
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
Stefan Zeuzem,1 Vicente Soriano,2 Tarik Asselah,3 Jean-Pierre Bronowicki,4 Ansgar W. Lohse,5 Beat Müllhaupt,6 Marcus Schuchmann7, Marc Bourliere,8 Maria Buti,9 Stuart Roberts,10 Ed Gane,11 Jerry O Stern,12 John-Paul Gallivan,13 Florian Voss,12 Wulf Böcher,13 Federico J Mensa12
1Klinikum der J. W. Goethe-Universitat, Frankfurt Am Main, Germany; 2Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain; 3Hopital Beaujon, Clichy, France; 4Hopital de Brabois, Vandoeuvre, France; 5University Hospital Hamburg-Eppendorf, Hamburg, Germany; 6University Hospital of Zurich, Zurich, Switzerland; 7University Hospital Mainz, Mainz, Germany; 8Hopital Saint Joseph, Marseille, France; 9Hospital Vall d'hebron and Ciberehd, Barcelona, Spain; 10Alfred Hospital, Department of Gastroenterology, Melbourne, Australia; 11Auckland Clinical Studies, Auckland, New Zealand; 12Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA; 13Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
|
| |
|
|
|
|
|
